- Home
- SHOP vs GILD Comparison
SHOP vs GILD Comparison
Compare SHOP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHOP | GILD |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7B | 187.4B |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | SHOP | GILD |
|---|---|---|
| Price | $174.87 | $154.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 54 | 28 |
| Target Price | ★ $175.71 | $159.85 |
| AVG Volume (30 Days) | ★ 8.7M | 4.8M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ 0.71 | N/A |
| Revenue | $11,556,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $31.97 | $4.36 |
| Revenue Next Year | $25.95 | $6.88 |
| P/E Ratio | $244.51 | ★ N/A |
| Revenue Growth | ★ 30.14 | 9.98 |
| 52 Week Low | $94.00 | $114.02 |
| 52 Week High | $182.19 | $160.51 |
Technical Indicators
Market Signals| Indicator | SHOP | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 64.41 | 56.89 |
| Support Level | $108.24 | $142.91 |
| Resistance Level | $180.88 | $157.29 |
| Average True Range (ATR) | 7.07 | 3.54 |
| MACD | 0.44 | 0.52 |
| Stochastic Oscillator | 79.91 | 64.83 |
Price Performance
Historical ComparisonAbout SHOP Shopify Inc.
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).